Research Analysts Set Expectations for Alphatec Q2 Earnings

Alphatec Holdings, Inc. (NASDAQ:ATEC) – Research analysts at HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for shares of Alphatec in a research note issued on Thursday, May 7th. HC Wainwright analyst S. Lee now forecasts that the medical technology company will earn ($0.12) per share for the quarter, down from their prior forecast of $0.01. HC Wainwright currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Alphatec’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Alphatec’s Q3 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.28) EPS and FY2028 earnings at $0.88 EPS.

Other analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, January 31st. Needham & Company LLC reduced their price objective on shares of Alphatec from $25.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Lake Street Capital reissued a “buy” rating and set a $15.00 target price on shares of Alphatec in a report on Wednesday, May 6th. TD Cowen dropped their target price on Alphatec from $20.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Finally, Barclays cut their price target on Alphatec from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Alphatec presently has an average rating of “Moderate Buy” and a consensus target price of $18.58.

Alphatec Price Performance

Shares of NASDAQ:ATEC opened at $7.57 on Friday. The firm has a market capitalization of $1.16 billion, a PE ratio of -9.23 and a beta of 0.96. The company has a quick ratio of 1.12, a current ratio of 1.90 and a debt-to-equity ratio of 40.35. The company has a 50-day moving average price of $10.86 and a two-hundred day moving average price of $15.56. Alphatec has a twelve month low of $6.82 and a twelve month high of $23.29.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Tuesday, May 5th. The medical technology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.21). Alphatec had a negative return on equity of 1,183.84% and a negative net margin of 15.93%.The firm had revenue of $192.11 million during the quarter, compared to analysts’ expectations of $197.51 million. During the same period last year, the business posted ($0.35) EPS. The company’s revenue was up 13.6% compared to the same quarter last year.

Insider Activity

In other Alphatec news, EVP David Sponsel sold 163,452 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $12.52, for a total value of $2,046,419.04. Following the sale, the executive vice president directly owned 504,932 shares in the company, valued at $6,321,748.64. This represents a 24.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Tyson Eliot Marshall sold 88,835 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $12.49, for a total transaction of $1,109,549.15. Following the completion of the transaction, the general counsel directly owned 559,459 shares of the company’s stock, valued at approximately $6,987,642.91. The trade was a 13.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 629,189 shares of company stock valued at $7,801,589 over the last ninety days. 13.48% of the stock is owned by insiders.

Institutional Investors Weigh In On Alphatec

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Creative Planning boosted its stake in Alphatec by 0.9% during the third quarter. Creative Planning now owns 58,654 shares of the medical technology company’s stock valued at $853,000 after buying an additional 534 shares during the period. Valeo Financial Advisors LLC increased its stake in Alphatec by 2.1% in the 3rd quarter. Valeo Financial Advisors LLC now owns 41,296 shares of the medical technology company’s stock worth $600,000 after acquiring an additional 846 shares during the last quarter. Arizona State Retirement System boosted its position in shares of Alphatec by 2.8% during the 3rd quarter. Arizona State Retirement System now owns 34,603 shares of the medical technology company’s stock valued at $503,000 after acquiring an additional 949 shares during the last quarter. Great Lakes Advisors LLC boosted its position in shares of Alphatec by 0.4% during the 4th quarter. Great Lakes Advisors LLC now owns 278,717 shares of the medical technology company’s stock valued at $5,864,000 after acquiring an additional 1,226 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Alphatec by 2.0% during the fourth quarter. Franklin Resources Inc. now owns 64,774 shares of the medical technology company’s stock worth $1,363,000 after purchasing an additional 1,299 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec News Summary

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: HC Wainwright still rates Alphatec Buy and kept a $24 price target, while raising its FY2028 EPS estimate to $0.88 from $0.75, signaling longer-term growth confidence.
• Neutral Sentiment: Separately, analyst commentary summarized post-earnings views on Alphatec, but did not add a major new operating development for the company.
• Negative Sentiment: HC Wainwright cut Alphatec’s Q2 2026 EPS estimate to ($0.12) from $0.01 and Q3 2026 EPS to ($0.06) from $0.01, reflecting weaker near-term profitability expectations.
• Negative Sentiment: The firm also lowered its FY2026 EPS estimate to ($0.28) from $0.09, suggesting Alphatec may remain unprofitable this year.
• Negative Sentiment: A separate report said Alphatec’s price target was reduced by 23.06% to $18.95, adding to bearish sentiment.
• Negative Sentiment: Two law firms announced securities fraud investigations into Alphatec after its May 5 earnings release, which can weigh on investor sentiment and increase legal overhang. Article Title

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.